Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib

TY - JOUR

T1 - Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib

AU - Zhou, Amy

AU - Kong, Tim

AU - Fowles, Jared S.

AU - Jung, Chun Ling

AU - Allen, Maggie J.

AU - Fisher, Daniel A.C.

AU - Fulbright, Mary

AU - Nemeth, Elizabeta

AU - Ganz, Tomas

AU - Oh, Stephen T.

N1 - Funding Information: This work was supported by NIH grants R01HL134952 (Stephen T. Oh) and T32HL007088 (Jared S. Fowles). Support for patient sample collection and processing was provided by NIH grant P01CA101937. CRP and Iron studies were run by the Core Laboratory for Clinical Studies (CLCS) at Washington University in St. Louis which is supported in part by the Washington University Diabetes Research and Training Centre (DRTC) and the Washington University Institute of Clinical and Translational Sciences (ICTS). Technical support was provided by the Alvin J. Siteman Cancer Centre Tissue Procurement Core Facility and Immunomonitoring Laboratory, which are supported by NCI Cancer Centre Support Grant P30CA91842. The Immunomonitoring Laboratory is also supported by the Andrew M and Jane M Bursky Centre for Human Immunology and Immunotherapy Programs. The authors thank D. Bender for assistance with multiplex cytokine measurement.

PY - 2022/5

Y1 - 2022/5

UR - https://www.scopus.com/pages/publications/85124481137

U2 - 10.1111/bjh.18044

DO - 10.1111/bjh.18044

M3 - Letter

C2 - 35128632

AN - SCOPUS:85124481137

SN - 0007-1048

VL - 197

SP - e49-e52

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 4

ER -